ENTX (Entera Bio) OCF Yield %: -11.27 (As of Jun. 27, 2026)


ENTX Entera Bio Ltd ENTX
23 GF Score
Price $1.63
! 2 Warning Signs
View Full Analysis

What is Entera Bio OCF Yield %?

Entera Bio ENTX +12.41% 23 OCF Yield % is -11.27 as of Jun. 27, 2026. GuruFocus rates ENTX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,419 Biotechnology companies, Entera Bio ranks worse than 59.06% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Entera Bio's Trailing 12-Month Cash Flow from Operations is $-9.06 Mil, and Market Cap is $80.34 Mil. Therefore, Entera Bio's OCF Yield % for today is -11.27%.

The historical rank and industry rank for Entera Bio's OCF Yield % or its related term are showing as below:

ENTX' s OCF Yield % Range Over the Past 10 Years
Min: -90.25   Med: -20.16   Max: -4.74
Current: -11.27


During the past 11 years, the highest OCF Yield % of Entera Bio was -4.74%. The lowest was -90.25%. And the median was -20.16%.

ENTX's OCF Yield % is ranked worse than
59.06% of 1419 companies
in the Biotechnology industry
Industry Median: -8.48 vs ENTX: -11.27

Entera Bio's OCF Margin % for the quarter that ended in Mar. 2026 was %.


Entera Bio OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Entera Bio OCF Yield % Related Terms


Entera Bio OCF Yield % Historical Data

* Premium members only.

The historical data trend for Entera Bio's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entera Bio OCF Yield % Chart

Entera Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.18 -59.43 -34.34 -8.28 -8.23

Entera Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.27 -7.55 -11.41 -8.18 -23.88

ENTX vs IMA, MNOV, ACRV: OCF Yield % Comparison

For the Biotechnology subindustry, Entera Bio's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entera Bio OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Entera Bio's OCF Yield % falls into.


ENTX
23GF Score
Entera Bio Ltd ENTX
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entera Bio OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Entera Bio's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-7.37 / 89.58726
=-8.23%

Entera Bio's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-3.09 * 4 / 51.75042
=-23.88%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -11.27 mean?
Entera Bio (ENTX) has a OCF Yield % of -11.27 as of Jun. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Entera Bio and its competitors. According to the industry distribution chart, Entera Bio ranks #838 out of 1419 companies in the Biotechnology industry, placing it in the top 59.1%.
Is Entera Bio's OCF Yield % too high?
Entera Bio's current OCF Yield % is -11.27. Based on the distribution chart, Entera Bio ranks #838 out of 1419 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Entera Bio has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's OCF Yield % compare to IMA and MNOV?
According to the Biotechnology industry distribution chart, Entera Bio ranks #838 out of 1419 companies for OCF Yield %. This places Entera Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Entera Bio and its competitors. Entera Bio's current OCF Yield % is -11.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Entera Bio (ENTX) has a current OCF Yield % of -11.27. The current OCF Yield % is -11.27. Entera Bio's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Entera Bio (ENTX), the current OCF Yield % is -11.27 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entera Bio Business Description

Other Exchanges 5DT:Germany
Address Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
23GF Score

Get the complete analysis for ENTX

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.63
Price